Tuberculosis (TB) remains the leading infectious disease killer, causing 1.5 million deaths, and an estimated 6 million new and 3.6 million undiagnosed cases annually. Despite being curable, TB is particularly devastating in the developing countries, where it claims 3 lives every minute. TB’s complexity stems from the different levels that require action. These include addressing detection and treatment gaps for both TB and MDR-TB in resource-limited settings, closing funding gaps, developing new diagnostic tools, and raising awareness. The real challenge in tackling TB is finding the right holistic approach to have an impact in the most affected communities, mobilizing all stakeholders, and implementing new social measures.
How can we design a new strategic partnership to leverage collective capacity and transform access to a continuum of diagnostics and therapeutic solutions at scale for TB and multidrug-resistant TB? This could enable Johnson & Johnson (J&J), the leading Fortune 500 healthcare company with a long history of improving access to needed medicines, and the non-profit FIND, the leading diagnostics innovator platform, to work together and achieve sustainable impact in low- and middle-income countries.
Global Development played critically important role in identifying synergies and converging objectives between Johnson & Johnson, FIND and our partners in the health ecosystem.Catharina Boehme, CEO FIND
GD led the development of a new partnership with FIND and Johnson & Johnson’s newly formed Global Public Health group to leverage joint capabilities by combining science and technology with innovative access models.We identified possible synergies and accelerated the convergence of the partners’ objectives to design a strategy for collaboration.
We outlined opportunities for J&J, FIND and their multiple innovation partners to collaborate on a variety of projects with other partners, including diagnostics developers and national TB control programs, to reduce the toll of more than 3 million people with undiagnosed TB globally, and more than 30% of people with diagnosed TB who are not appropriately treated.
GD was instrumental in fast-tracking afirst-of-its-kind strategic collaboration between diagnostic and pharmaceutical partners tostrengthen the links to effective treatment following diagnosis, greatly improving access to diagnosis for drug-resistant TB.